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Abstract
Background: There is a growing interest on the impact of comorbid obsessive-compulsive symptoms (OCS) on the course and severity of schizophrenia in 
recent years. Objectives: This study determined the prevalence of OCS in schizophrenia patients and the clinical outcomes of the comorbidity. Methods: 
A total of 220 schizophrenia patients were recruited. All the participants completed Structure Clinical Interview version, Yale Brown Obsessive Compulsive 
Scale, Calgary Depression Scale for Schizophrenia, Columbia Suicide Severity Rating Scale and World Health Organization Quality of Life – Brief Version 
(WHOQOL-BREF). Results: Significantly higher number of schizophrenia patients with OCS were taking Clozapine (p = 0.023) and antidepressants (p = 0.013). 
Schizophrenia patients with OCS showed more severe positive (p < 0.001) and general symptoms (p < 0.001) of schizophrenia, higher depressive symptoms 
(p = 0.013), higher suicidality (p < 0.001), more hospitalization (p = 0.044), poorer physical (p = 0.034) and psychological (p = 0.032) domain in WHOQOL-
BREF. Discussion: Schizophrenia patients with OCS are associated with more severe psychopathology and depressive symptoms which subsequently suffered 
poorer physical and psychological health. Hence, recognition of OCS in schizophrenia and early initiation of effective treatment may be able to reduce the 
burden for people with chronic mental illness. 
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Introduction
Schizophrenia is a long-term serious psychotic disorder characterized 
by main clinical features of hallucinations, delusions, disorganized 
thoughts, changes in behavior, and negative symptoms. Over 
the years, clinicians and researchers paid less attention to non-
psychopathological manifestations among the schizophrenia patients, 
one of which is the obsessive-compulsive symptoms (OCS). Despite a 
wide variation of prevalence noted in many parts of the world, ranging 
from 1.1% to 50%1, a more recent study observed that the pooled 
prevalence was 30.7%2. OCS in schizophrenia were once thought 
to be rare and benign in nature, however some recent studies have 
shown not only greater prevalence rate but poorer outcome among 
these patients3. Interestingly, many researchers were facing difficulties 
to generalize the findings as there were no standard criteria available 
to determine the presence of clinically significant OCS, as compared 
to obsessive compulsive disorder which can be clearly categorized in 
Diagnostic and Statistical Manual of Mental Disorder (DSM).
In the past, obsession had not only been postulated to protect 
against psychosis and thought disorganization4 but also believed to 
prevent “personality disintegration” in schizophrenia5. However, 
these findings were not reproducible in subsequent studies, which 
found that schizophrenia with OCS had actually worse outcomes6,7. 
Two years ago, a group of researchers again proved that patients 
suffering from schizophrenia with OCS had significantly higher 
scores in both the Positive and Negative Syndrome Scale (PANSS) 
and Beck Depression Inventory (BDI) when compared to the non-
OCS group8. Furthermore, higher rates of suicidal plans or attempts 
were also found among these patients9,10. There were findings from 
various studies to suggest that schizophrenia with OCS might be 
a distinct subtypes of schizophrenia7,11,12; and that OCS itself was 
considered as one of the core clinical features and symptom domains 
of schizophrenia rather than being an additional clinical condition6.
There are growing evidence to suggest the existence of a 
schizo-obsessive compulsive disorder (Schizo-OCD) subtype 
of schizophrenia. This subtype is shown to manifest different 
neuropsychological and clinical outcomes among the schizophrenia 
patients. A proposed diagnostic criteria for Schizo-OCD was available 
since 201213. In that proposed criteria, criterion A of OCD must be 
present at some point in time during the course of schizophrenia. 
In addition, the obsession/compulsion must be present in 
substantial amount of time and must not be related to the delusion 
or hallucination from schizophrenia. Neurological soft signs (NSS) 
were defined as “minor neurological signs which reflect dysfunction in 
areas of motor coordination, integrative sensory function and ordering 
complex motor tasks, but the dysfunctions are not localizable to specific 
brain structure”14,15. Studies showed that Schizo-OCD scored higher 
in the Neurological Evaluation Scale (NES) compared to healthy 
controls16,17, but no difference when compared with schizophrenia 
alone. These findings have further suggested that Schizo-OCD may 
be a distinct subtype of schizophrenia, and not merely a more severe 
form of OCD. In addition, previous studies had consistently reported 
there were no significant differences between OCS in obsessive 
compulsive disorder (OCD) and Schizo-OCD in term of clinical 
characteristics18,19. Faragian et al. reported that the symptoms in 
Schizo-OCD were comparable to those revealed in “pure” OCD. The 
author concluded that the universal mechanisms were involved in the 
pathogenesis of OCD regardless of the presence of schizophrenia18,19. 
Contradictions on the effects of atypical anti-psychotic (AAPs) 
medications such as clozapine on schizophrenic patients still exist. 
The risk of AAPs-induced OCS has been reported in many studies20-22. 
AAPs with higher serotonergic activities has higher propensities 
in inducing OCS23. Clozapine stands out as the most frequently 
reported AAPs to induce OCS due to its highest propensity in 
serotonergic activities24,25. In contrary, existing literatures also showed 
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that AAPs such as Aripiprazole and Risperidone to be effective in 
the augmentation of selective serotonin reuptake-inhibitor (SSRI)-
resistant OCD26,27. In addition, AAPs with strong dopamine receptor 
2 (D2) blockade were reported to be effective in treating Schizo-OCD. 
Some studies, however, found no significant difference between 
schizophrenia with or without OCS in terms of their psychopathology 
and suicidality28-30. We believe that this finding could have been a 
result of different methodological approach. Studies which recruited 
inpatients tended to reflect a higher severity in psychopathological 
domains6,7 as compared to those which studied on patients 
recruited from the outpatient settings28,29. During acute episodes 
of psychosis, it would also be very difficult to discern obsessions 
from delusions of schizophrenia31. In addition, some studies had 
used different definitions for clinically significant OCS resulted in a 
non-homogenous recruitment of study participants8,32, while some 
researchers had shown that both obsessive-compulsive disorder 
(OCD) and schizophrenia with OCS were no different in terms of 
their obsessive and compulsive symptom structures18. 
Since the co-occurrence of OCS and schizophrenia had always 
been an interesting topic of discussion and a real challenge faced by 
the treating clinicians, but studies had mainly been done in the western 
countries, we decided to conduct this study in Malaysia to determine 
the prevalence of OCS among a group of stable schizophrenia patients 
attending a tertiary hospital outpatient clinic. In addition, our study 
also intended to resolve any conflicting evidence in literatures and 
examine the clinical variables of OCS in schizophrenia.
Methods
Subjects
In this cross-sectional study, participants consisted of stable 
outpatients who were attending their follow up sessions in the 
psychiatric clinic in University Malaya Medical Center (UMMC) 
– a tertiary hospital situated in Kuala Lumpur, Malaysia – between 
August 2014 and July 2015. All recruited participants were diagnosed 
with schizophrenia based on Diagnostic and Statistical Manual for 
Mental Disorder, Fifth Edition (DSM-V), understood English or 
Malay language and were on the same antipsychotic treatment for at 
least six months. Patients were excluded if (1) they were having active 
psychotic symptoms, which would affect their capacity for informed 
consent; (2) they had intellectual disability and dementia, and (3) 
patients who refused to participate. The study was approved by the 
UMMC medical ethics committee. All participants were thoroughly 
briefed on the study protocol and their informed consent obtained.
After participants’ demographic data were obtained from the case 
files, all the participants were assessed by the author using Yale Brown 
Obsessive Compulsive Scale (YBOCS) Symptoms Checklist, Yale-
Brown Obsessive Compulsive Scale (YBOCS), Positive and Negative 
Symptoms for Schizophrenia (PANSS), Calgary Depression Rating 
Scale (CDSS), Columbia Suicide Severity Rating Scale (C-SSRS) and 
World Health Organization Quality of Life Scale Brief Malay Version 
(WHOQOL-BREF).
Demographic variables
The socio-demographic questionnaire was used to record relevant 
information about the participants of this study which included 
age, gender, ethnic group, marital status, education level, religion, 
employment status, family mental history, duration of illness and 
type of medication. Participants were instructed to complete the 
questionnaire by filling in the blanks and selecting one response 
that best described them. 
Obsessive compulsive symptomatology
Obsessive compulsive symptoms (OCS) were first screened with Yale 
Brown Obsessive Compulsive Scale (YBOCS) Symptoms Checklist. 
Subsequently, patients were assessed with YBOCS33 to determine 
the severity of their OCS. It consists of 2 subscales; obsession and 
compulsion. Total YBOCS score was used to assess the severity of 
OCS. In this study, clinically significant OCS was defined as total 
YBOCS score of 8 and above. YBOCS was suitable in the assessment 
of OCS in Schizophrenia34. 
Schizophrenia psychopathology
Severity of schizophrenia symptoms were assessed using the 
Positive and Negative Syndrome Scale (PANSS)35 with the help of 
the Structure Clinical Interview version (SCI-PANSS). PANSS is a 
well-defined instrument to assess positive, negative as well as general 
symptoms in patients with schizophrenia. The higher the score, the 
more severe the psychopathologies. PANSS has 3 main sub-scales, 
namely positive, negative and general psychopathology. Overall, total 
PANSS score reflected the severity of schizophrenia.
Depressive symptomatology
In this study, we utilized the Calgary Depression Scale for 
Schizophrenia (CDSS)36 to assess participants’ depressive symptoms. 
CDSS contains nine items. Each item consists of 4 options – 0 for 
absent, 1 for mild, 2 for moderate and 3 for severe symptoms. Higher 
score represents worse depressive symptoms.
Suicidality assessment
Suicidality in the present study was assessed using the Columbia 
Suicide Severity Rating Scale (screening version) (CSSR-S)37. 
Suicidality is defined as any suicidal behavior or ideation during 
the period of assessment according to the scoring and data analysis 
guide for CSSR-S. In this study, dichotomous outcome was used to 
ascertain presence or absence of suicidality.
Quality of life assessment
Participants’ quality of life was assessed by using the 26-item World 
Health Organization Quality of Life – Brief Version (WHOQOL-
BREF). A validated Malay Version of WHOQOL-BREF38 was 
used in this study. Four domains were assessed, namely physical, 
psychological, social and environmental which denotes individuals’ 
perception of their quality of life in each domain. Higher score 
denotes higher quality of life. WHOQOL-BREF (M) score was 
transformed into domain score comparable with the score used in 
WHOQOL-100 for data analysis according to the provided guideline.
Statistical analysis
All statistical analysis was performed using the Statistical Package for 
Social Sciences (SPSS) Version 22.0. Normal distribution of quantitative 
data was assessed using the Shapiro-Wilk test. Chi Square Test and Fisher 
Exact Test were used when necessary to compare categorical variables 
between schizophrenia with OCS and without OCS. Mann Whitney’s U 
test was used to compare non-normally distributed continuous variables. 
Analysis of Covariance (ANCOVA) was performed to control the effect 
of chronicity of illness which was assessed empirically using duration 
of illness and the use of clozapine mainly for treatment resistance 
schizophrenia. Spearman’s correlation was performed to examine the 
possible correlation between obsessive compulsive symptoms and 
schizophrenia psychopathology. Finally, logistic regression was carried 
out to analyze independent variables which were associated with OCS 
in schizophrenia. Level of significance was set at p < 0.05. 
Results
Demographic data
A total of 220 outpatients were recruited. There was equal gender 
distribution between males (48.6%) and females (51.4%). Mean age 
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for the participants was 43.7 years old (SD = 12.4). Majority of the 
participants were Chinese (57.7%), followed by Indian (23.6%), 
Malay (15.6%) and others (2.7%). More than two third of the study 
participants were single (70.0%) and their majority were unemployed 
(76.8%). Patients were divided into two groups; schizophrenia with 
OCS and without OCS. There was no significant difference in terms 
of age, gender, race, education level, employment status, duration of 
illness and family history of any psychiatric illness between the two 
groups. In addition, the use of antipsychotic drug classes (both first 
and second generations) were of no significant difference between 
the schizophrenia patients with OCS and those without. However, 
significantly higher number of schizophrenia patients with OCS 
were taking Clozapine at the time of recruitment (odds ratio = 2.267, 
p = 0.023) (Table 1).
Table 1. Comparison between Schizophrenia with and without OCS
OCS
OR or U 95% CI or Z P valueYes (n = 48) 
N (%)
No (n = 172)
N (%)
Age, median 38 (98.14)c 44 (113.95)c 3535.50a -1.523b 0.128
Male 24 (50.0) 83 (48.3) 0.933 0.492 – 1.769 0.871
Female 24 (50.0) 89 (51.7)
Chinese 24 (50.0) 103 (59.9) 0.670 0.352 – 1.274 0.249
Non-Chinese 24 (50.0) 69 (40.1)
Malay 8 (17.0) 27 (15.7) 0.908 0.382 – 2.155 0.824
Non-Malay 39 (83.0) 145 (84.3)
Indian 15 (31.3) 37 (21.5) 1.658 0.815 – 3.375 0.180
Non-Indian 33 (68.8) 135 (78.5)
Single 35 (72.9) 119 (69.2) 0.834 0.408 – 1.703 0.723
Married 13 (27.1) 53 (30.8)
Secondary and below education 30 (62.5) 129 (75.0) 1.800 0.913 – 3.548 0.102
Tertiary education 18 (37.5) 43 (25.0)
Employed 10 (20.8) 41 (23.8) 0.841 0.385 – 1.834 0.847
Unemployed 38 (79.2) 131 (76.2)
Family history of mental illness
Yes 20 (41.7) 55 (32.0) 1.519 0.788 – 2.932 0.230
No 28 (58.3) 117 (68.0)
Duration of illness
Less than 5 years 8 (16.7) 24 (14.0) 0.811 0.339 – 1.941 0.646
5 years and above 40 (83.3) 148 (86.0)
Antipsychotics
Typical 6 (12.5) 42 (24.4) 0.171
Atypical 35 (72.9) 112 (65.1)
Combination 7 (14.6) 18 (10.5)
Clozapine 30 (62.5) 36 (20.9) 2.267 1.137 – 4.520 0.023*
Olanzapine 8 (16.7) 30 (17.4) 0.947 0.403 – 2.226 1.000
Risperidone 9 (18.8) 50 (29.1) 0.563 0.254 – 1.248 0.197
Antidepressant 15 (31.3) 23 (13.4) 2.945 1.388 – 6.246 0.008**
Clinical variables
More than 5 admissions 29 (60.4) 133 (77.3) 2.234 1.132 – 4.409 0.026*
Antidepressant prescription 15 (31.3) 23 (13.4) 2.945 1.388 – 6.246 0.008**
Suicidality 27 (56.3) 45 (26.2) 3.629 1.868 – 7.048 < 0.001**
PANSS Positive 139.65c 102.37c 2729.00a -3.603b < 0.001**
PANSS Negative 121.39c 107.46c 3605.50a -1.343b 0.179
PANSS General 133.22c 104.16c 3038.00a -2.801b 0.005**
PANSS Total 133.22c 104.16c 3037.50a -2.798b 0.005**
CDSS 134.31c 103.85c 2985.00a -3.183b 0.001**
Physical QOL 93.34c 115.29c 3304.50a -2.121b 0.034*
Psychological QOL 93.13c 115.35c 3294.00a -2.147b 0.032*
Social QOL 105.22c 111.97c 3874.50a -0.656b 0.512
Environmental QOL 104.97c 112.04c 3862.50a -0.683b 0.494
a Median are compared with Mann Whitney’s U test with b Z score.
b  Median are compared with Mann Whitney’s U test  with b Z score.
c Non-normally distributed variables are expressed in mean rank.
Categorical variables with Fisher exact test.
* Significant level at p < 0.05.
** Significant level at p < 0.01.
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Prevalence of OCS in Schizophrenia
In this study, we found that the prevalence of OCS in schizophrenia 
was 21.8% by using the total YBOCS score of 8 and above (N = 48). 
The most common obsessions were aggression (8.2%), contamination 
(8.2%) and miscellaneous (7.8%). For compulsion, the most 
commonly elicited compulsion was checking (8.2%) and cleaning/
washing (7.8%).
Clinical variables of schizophrenia with OCS
Spearman’s correlation was performed and showed that obsession 
was significantly correlated with positive symptoms (r = 0.292, 
p < 0.001) and general symptoms (r = 0.217, p = 0.001) of 
schizophrenia. For compulsions, results showed they were 
significantly correlated with positive symptoms (r = 0.195, p = 0.004). 
In this study, the group of schizophrenia patients with OCS 
documented significantly more hospitalizations (OR = 2.234, 
p = 0.026), higher number of prescription of antidepressants (odd 
ratio = 2.945, p = 0.008) and higher suicidality rate (OR = 3.629, p < 
0.001). The same group of patients also scored higher in the PANSS 
positive subscale (n = 48, U = 2729.00, p < 0.001), general subscale 
(N = 48, U = 3038.00, p = 0.005), total PANSS (N = 48, U = 3037.50, 
p = 0.005), and CDSS total score (N = 48, U = 2985.00, p = 0.001). 
In addition, schizophrenia patients with OCS were also found to be 
associated with poorer physical quality of life (N = 48, U = 3304.50, 
p = 0.034) and poorer psychological quality of life (N = 48, U = 
3294.00, p = 0.032) (Table 1). 
We continued to observe statistically significant differences 
between schizophrenia patients with OCS and those without, as 
reflected in the PANSS positive subscale, PANSS general symptoms 
subscale, PANSS total score and CDSS score (Table 2) after all 
the confounders were adjusted. For categorical clinical variables, 
logistic regression was performed by using illness chronicity as the 
covariate. Results showed the number of hospitalization; presence 
of suicidality and the use of antidepressant were significantly higher 
in schizophrenia patients with OCS (Table 3).
Discussion
From this study, we found that the prevalence of OCS among 
schizophrenia patients in our setting is 21.8%. This figure is very 
closed to the finding of a study done in another Asian country, Korea, 
which revealed a prevalence of 21.1%21. Nevertheless, our figure is 
lower when compared to the prevalence of 30.7% documented in a 
meta-analysis done in 20142. Despite many studies conducted on 
this topic over the decades, there are still no universally accepted 
criteria for the diagnosis of OCS in schizophrenia. We believe that 
this shortcoming may have further complicated the estimation of 
prevalence of OCS in schizophrenia. In addition, studies which 
recruited inpatients6,7,39 and outpatients29,40,41 also showed a large 
difference in the prevalence of the comorbidity.
In terms of the socio-demographic factors between schizophrenia 
patients with OCS and those without, we observed that the duration 
of illness is not significantly associated with the presence of OCS 
in schizophrenia. This is in contrast with previous studies which 
reported that the longer the illness, the higher the prevalence of 
OCS in schizophrenia2,8,42. As expected, the usage of clozapine in 
schizophrenia was associated with high OCS, a finding consistent 
with previous studies25,43-45. It was postulated that high propensity of 
anti-serotonergic properties in clozapine could lead to or exacerbate 
serotonin deficiency, which subsequently trigger the onset of OCS 
and yield a full threshold OCD22,24. This iatrogenic mental disorder 
would pose additional challenge to the treatment. Clozapine is the 
only second generation antipsychotic that is effective in the treatment 
of resistant schizophrenia (TRS)46. Previous studies have identified 
few treatment options for clozapine induced OCS. One of the 
treatments is to combine Aripiprazole with Clozapine. Aripiprazole 
is a second-generation antipsychotic with few trials already carried 
out showing its effectiveness in treating Clozapine induced OCS in 
TRS. TRS patients who received the combination of Aripiprazole-
Clozapine not only had reduced total YBOCS score at one month 
after treatment, but also showed better tolerability47 and improvement 
in quality of life48 as compared to Clozapine-placebo group49. In 
fact, by adding on a Selective Serotonin Reuptake Inhibitor (SSRI) 
it is more effective in treating induced OCS, in cases of treatment-
resistant schizophrenia which normally only responds to clozapine. 
Escitalopram50, fluvoxamine51 and fluoxetine52 had shown their 
effectiveness in treating induced OCS. However, more trials needed 
to be done to identify the most effective medication to be used in 
clozapine induced OCS in treating TRS. 
In some of the previous studies, it was reported that 
schizophrenia patients with OCS were associated with more severe 
psychopathology7,8 and depressive symptoms9,10,40,53. Our study 
findings are consistent with these previous studies, as our patients 
also had more psychotic symptoms and higher depressive symptom 
scores. These findings were not influenced by chronicity of illness 
in the participants, as well as the concurrent use of Clozapine. 
Furthermore, the presence of OCS had been associated with higher 
suicidality in patients with schizophrenia12, 54 in which our study also 
revealed similar finding. This is clinically important as practicing 
clinicians ought to be aware of the impact of OCS, hence be more 
vigilant when assessing this group of patients for suicidality.
Our study also noted poorer physical and psychological quality 
of life among these schizophrenia patients with OCS. These findings 
are in line with a recent study conducted in Amsterdam which 
revealed that comorbid OCS in schizophrenia was associated with 
a lower mean across all domains, namely subjective wellbeing, social 
integration, emotional regulation, physical and mental health41. 
Similar findings were also reported by Tiryaki and Özkorumak in 
their study involving 62 patients with schizophrenia and OCS 6. Thus, 
we need to create awareness among all practicing clinicians when 
they treat comorbid OCS, as this will contribute in the improvement 
of patients’ quality of life55.
Some limitations were present in our study. Firstly, by the nature 
of a cross-sectional design of our study, we were unable to explore 
the causal relationship between the presence of OCS and clinical 
Table 2. Comparison between Schizophrenia with or without OCS in clinical 
variables (PANSS, CDSS and WHOQOL-BREF) using analysis of covariance 
(ANCOVA), Generalized Linear Models after controlled for chronicity of 
illness in the study sample
OCS
Mean 
difference P valueYes (n = 48) 
(Mean)
No (n = 172) 
(Mean)
PANSS
Positive 14.98 12.56 2.42 < 0.001**
General 25.78 22.95 2.82 0.001**
Total 55.57 49.39 6.18 < 0.001**
CDSS Total 3.79 2.10 1.69 < 0.001**
WHOQOL-BREF
Physical 62.35 57.12 5.23 0.145
Psychological 57.71 59.20 1.51 0.679
P value significant level at P < 0.01**.
Table 3. Logistic regression for clinical variables using chronicity of illness 
as covariate: hospitalization, suicidality and use of antidepressant
Variables B SE Exp (B) P value
Hospitalization 0.744 0.369 2.105 0.044*
Suicidality 1.257 0.348 3.516 < 0.001**
Use of antidepressant 0.974 0.392 2.650 0.013*
P value significant level at p < 0.05*, p < 0.01**.
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variables. Secondly, there was no universally accepted criteria 
to diagnose OCS in schizophrenia. Previous studies had used 
different criteria to diagnose OCS which produced variabilities in 
their study outcome. Thirdly, since this study was done at a local 
outpatient setting, the findings could not be generalized to other 
parts of the world. Thus, further systematic studies are needed 
in near future to explore the diagnostic criteria for OCS and a 
prospective study design to determine the causal relationship of 
OCS in schizophrenia. 
Schizophrenia with OCS remains prevalent in many parts of the 
world. The awareness of this non-schizophrenia psychopathological 
comorbid among practicing clinicians is crucial as this is a different 
entity of psychiatric disorder needing special attention and treatment 
approach. Gross oversight of this comorbid will result in severe 
depressive symptoms and higher suicidality. In addition, clinicians 
need to also be aware of the pro-obsessive effect of Clozapine in 
the treatment of refractory schizophrenia. It is our hope that more 
attention will be given to this prevalent condition through rigorous 
research within this area in near future.
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